Zinc Finger Fusion Proteins for Prion Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for prion diseases, such as Creutzfeldt-Jakob Disease, are limited in effectively reducing prion protein (PrP) expression, which is crucial for halting the progression of the disease, as existing methods like antisense oligonucleotides have limitations in distribution and efficacy.
Innovation Solution
Development of zinc finger protein (ZFP) domains that specifically target the PRNP gene, fused with a transcription repressor domain to inhibit PrP expression in mammalian cells, potentially achieving higher repression levels with fewer off-target effects and requiring less frequent administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense oligonucleotides are used to reduce PrP expression, then PrP knockdown is achieved, but distribution and efficacy are limited
Solution Approach 1:
The patent replaces the chemical mechanism of antisense oligonucleotides with a protein-based mechanism (zinc finger protein transcription factors). This substitution enables nuclear localization and direct interaction with the PRNP gene promoter, achieving superior distribution and efficacy in reducing PrP expression compared to the previous chemical approach.
Solution Approach 2:
The patent changes the mechanism of action from post-transcriptional (antisense oligonucleotides) to transcriptional (ZFP-TFs binding to promoter). This parameter change in the level of gene regulation achieves more effective and widespread PrP expression reduction, resolving the limitations of previous methods.
2Reliability
If higher levels of PrP knockdown are achieved, then therapeutic benefit is improved, but existing methods have limited distribution
Solution Approach 1:
The patent substitutes the limited distribution mechanism of antisense oligonucleotides with the nuclear localization mechanism of ZFP-TFs. The transcription factors are delivered via AAV vectors that target the nucleus, enabling high-level PrP knockdown throughout the central nervous system with superior distribution.
Solution Approach 2:
The patent introduces AAV vectors as intermediaries to deliver ZFP-TFs to the nucleus. This intermediary mechanism enables widespread distribution of the transcription factors throughout the central nervous system, achieving high-level PrP knockdown that was not possible with direct antisense oligonucleotide administration.
3Reliability
If existing therapeutic methods are used, then treatment is provided, but administration frequency is high
Solution Approach 1:
The patent replaces the transient effect of antisense oligonucleotides with the long-lasting epigenetic modification mechanism of ZFP-TFs. The transcription factors induce stable changes in chromatin structure and gene expression, enabling prolonged therapeutic effect that reduces administration frequency.
Solution Approach 2:
The patent employs preliminary action through epigenetic modification of the PRNP gene promoter. The ZFP-TFs induce stable chromatin changes that persist over time, creating a long-lasting therapeutic effect that reduces the need for frequent re-administration compared to transient antisense oligonucleotide treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ZFP domains effectively repress PrP expression in brain cells, potentially delaying the onset and progression of prion diseases, offering a more potent and targeted therapeutic approach compared to existing methods.
Implementation Method 1
The ZFP domains of the present disclosure may be fused to a transcription factor to specifically inhibit the mammalian PRNP gene at the DNA level
Implementation Method 2
a transcription repressor domain that reduces the transcription of the gene
Data Source
AI summary
The present disclosure provides zinc finger fusion proteins that inhibit expression of the prion gene in the nervous system, and methods of using the proteins to treat prion disease.